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Abstract
Background: Cytomegalovirus infection dramatically decreased with the introduction of antiretroviral therapy.
Whether incidence, clinical characteristics and prognosis of cytomegalovirus in HIV infected patients, has changed
over time is. scarcely known.
Methods: Retrospective single-center study. Patients included in this study were all HIV infected patients that went
to our center for any disease, and were diagnosed with cytomegalovirus, during the period 2004–2015.
epidemiological, clinical and laboratory patients variables were collected in a clinical database. Clinical
characteristics, incidence of cytomegalovirus and predictors of mortality during the study were assessed. Results
were considered statistically significant when p < 0.05. All statistical analyses were calculated by SPSS version 20.0
(Chicago, IL,USA).
Results: Fifty-six cases of cytomegalovirus infection, in HIV infected patients were identified during the study period
(incidence rate-1.7 cases per 1000 persons/year). The most frequent presentation was systemic illness in 43% of
cases. Of note,no patients presented with ophthalmic manifestations. The 30-days mortality was 18%. Predictors of
mortality were, in the univariate analysis, admission to the intensive care unit OR 32.4 (3.65–287.06) p = 0.0001, and
mechanic ventilation 84 OR (8.27–853.12) p = 0.0001, and ART OR 4.1 (0.97–17.31) p = 0.044. These variables were
assessed by multivariate analysis, and only mechanical ventilation was statistically significant (p < 0.05)
Conclusion: Incidence of cytomegalovirus infection was higher than described in the antiretroviral therapy era.
Clinical presentation has changed. Mechanic ventilation predicted mortality.
Background
Cytomegalovirus infection (CMVI), is an AIDS-defining
condition that is now much less frequent than in the
past due to the widespread availability of combination
antiretroviral therapy (ART) [1]. Prior to the introduc-
tion of ART approximately 40% of HIV infected patients
with advanced immunosuppression suffered from mani-
festations of an CMVI during their life-time [2].
Different studies suggest that Cytomegalovirus (CMV)
is a cofactor for rapid HIV-1 disease progression [3], and
CMV has been associated with inflammation and im-
mune activation in HIV-infected patients [4], but
detecting CMVI is not an AIDS-defining condition per
se. Positive viremia has been reported as a predictor of
end-organs CMV disease, and along with low CD4
counts it is associated with increased mortality regard-
less of the plasma HIV RNA [5]. Among HIV/AIDS pa-
tients, CMV may present with a wide range of clinical
manifestations and results in a significant exacerbation
of morbidity and mortality [6]. The most common mani-
festations classically reported included retinitis, followed
by esophagitis and colitis [7, 8]. It usually developed in
patients with very low CD4 cell counts (< 50/mm3), and
clinicians had to be aware of the possibility of multior-
gan involvement [9].
Methods to detect and quantify CMV in clinical sam-
ples have been improving over the past few years and
have been standardized into clinical routine as important
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diagnostic tools in patients at risk, including HIV-
infected patients [10, 11]. We aimed to review how
CMVI may have changed in HIV-infected patients in re-
cent years, now that CMV DNA testing is available for
clinical routine. The objectives of this study were to de-
termine the incidence of CMVI in an institution caring
for a large cohort of HIV-infected adults, to describe the
clinical characteristics of CMVI, and to identify factors
associated with a worse prognosis, defined by 30-day




This is a retrospective single-center study at a large uni-
versity hospital caring for HIV-infected patients in
Barcelona, Spain. All HIV infected patients, with at least
one visit in the HIV clinical database, presenting with
any symptoms which required hospital admission, and
resulted in the diagnosis of CMVI (1st episode), were in-
cluded in this study. If some patients had to be trans-
ferred to another hospital or left the hospital without
medical consent, they were excluded from the study.
The follow-up time ended when the patient was dis-
charged. We chose the period starting on 1 January 2004
because of the availability of CMV DNA testing from
that time onwards. Censorship was 31 December 2015
for the patients not diagnosed with CMV unless death
or loss of follow-up.
Definitions
CMVI is defined as virus isolation or detection of viral
proteins (antigens) or nucleic acid in any body or fluid
or tissue [13]. CMV disease consists of “end-organ dis-
ease” and CMV syndrome. To define “proven CMV end-
organ disease”, the presence of appropriate clinical
symptoms and/or signs are required together with docu-
mentation of CMV in tissue from the relevant organ by
histopathology, virus isolation, rapid culture, immuno-
histochemistry, or DNA hybridization. There was no
checking for CMV infection in the absence of symptoms.
Definitive diagnosis of tissue-invasive disease relies on
detection of CMV in the tissue specimens, however; bi-
opsy obtention is not always feasible (the diagnosis of
tissue-invasive CMV disease should be confirmed by im-
munohistochemistry or in situ DNA hybridization. How-
ever, this information was not available in the patients
included in our study). CMV syndrome is defined as the
presence of fever (> 38 °C) for at least 2 days in a 4-day
period associated with the presence of leucopenia,
thrombocytopenia or an increase in transaminases, plus
evidence of CMV replication [12, 13]. As per clinical
routine protocol, all HIV-infected patients diagnosed
with CMV were checked for fundoscopy to rule out ret-
inal CMV involvement.
Clinical variables
For the purpose of this study, the following epidemio-
logical, clinical and laboratory variables were collected:
sex, age, associated co-morbidities [14], route of HIV
transmission, smoking, alcohol, use of illicit drugs, treat-
ment with ART, previous opportunistic infections, most
recent CD4 and CD8 lymphocytes, most recent plasma
HIV viral load, co-infection with hepatitis C virus (HCV),
target organ of CMV, the presence of fever, need for
mechanical ventilation, the total number of white blood
cells, platelets, hemoglobin, liver profile, plasma CMV
viral load at admission to ICU and 30-day mortality.
Laboratory studies
Molecular detection of CMV was performed by real-time
quantitative PCR ELITechGroup NANOGEN, Italy) after
extraction of DNA with DSP Virus/Pathogen Midi kit
(Quiagen, Germany) in a QIAsymphony automated plat-
form (Qiagen, Germany. The PCR was done on plasma,
BAL fluid and biopsy tissue. The BAL samples were inoc-
ulated into human fibroblasts (MRC5) and incubated for
4 weeks on a roller drum at 35 °C. CMV was identified on
the basis of cytopathic effect in cell cultures, and their
identification was confirmed by staining with fluorescein-
conjugated monoclonal antibodies as was previously
described (Monofluo Kit CMV,BioRad, France) [15]. Bac-
terial identification and antibiotic susceptibility tests, and
viral culture, were performed according to EUCAST rec-
ommendations [16]. Pneumocystis jirovecii was detected
by Gomori methenamine silver staining, we did not use
PCR. Some patients presented insolation in BAL P jiroven-
cii and CMV, but we could not affirm that it was affect-
ation of the end organ since it was not possible to perform
pulmonary biopsy for CMV. The detection of Toxoplasma
gondii was done by serology.
End point
We aimed to determine the incidence of CMVI in the
ART era, the global incidence, divide it into the periods
of 2004–2010 and 2011–2015, describe the clinical char-
acteristics of CMV, and identify factors associated with a
worse prognosis as defined by 30-day mortality and the
need for ICU admission.
Statistical analysis
Categorical variables were expressed as frequencies and
percentages, and continuous variables as median and
interquartile range (IQR). For independent samples, Stu-
dent’s t-test or U-Mann Whitney test as appropriate was
used to evaluate the relationship between quantitative
variables. The chi-squared test was selected to evaluate
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the relationship between qualitative variables. To calcu-
late the incidence rate we used the number of new cases
of CMVI during the specified time interval, in the nu-
merator, divided by the summed person-years of obser-
vation during the time interval, in the denominator.
Factors associated with ICU admission and mortality
were assessed by multivariate analysis (including some
analytic and demographic baseline characteristics as co-
variates). Results were considered statistically significant
with p < 0.05. All statistical analyses were calculated by
SPSS version 20.0 (Chicago, IL, USA).
Results
Incidence
Out of 7155 adults cared for between 1 January 2004 and
31 December 2015 contributing to 32,198 HIV patient-
years of follow-up care, 56 cases of CMVI were identified
in the study period. The incidence rate was 1.7 cases per
1000 patient-years, with a median follow up of 4.5
IQR(2.7–6.3) years The incidence rate of CMVI increased
significantly from the 2004–2010 period, 0.6 cases per
1000 patient-years, (14 cases in 4293 patients, contributing
to 22,865 patient-years) to the 2010–2015 period, 4.5
cases per 1000 patient-years, (42 cases in 2862 patients
contributing to 9333 patient-years), (p < 0.001).
Patients
The median age was 39 (IQR 15.8) years old, 44 cases
(79%) were males, 6 (11%) were co-infected with hepa-
titis C virus (HCV) (Table 1). The median CD4 was 47.0
(IQR 212) cells/μl, the median viral load (VL) of HIV
was 228,350 (IQR 689725) copies/ml. The median CMV
VL in blood was 40,829 (IQR 85) copies/ml, and the
mean CMV VL in BAL was 58.7 (IQR 1466.7) copies/ml.
CMVI was diagnosed within 3 months after being diag-
nosed with HIV in 20 (36%) patients, 36 patients were
known to be more chronically (defined as more than
3 months apart) HIV-infected prior to CMVI. Twenty
six patients were not on antiretroviral therapy at the
time of the diagnosis of CMVI. Eighteen were
antiretroviral-naive, while eight had previously taken
antiretroviral therapy. For those patients on antiretro-
viral therapy (n = 30), 25 were on a protease inhibitor-
containing regimen, 4 on a non-nucleoside reverse
transcriptase inhibitor-containing regimen, and 1 on an
integrase inhibitor-containing regimen. Of the 30 pa-
tients on antiretroviral therapy when CMVI was diag-
nosed median (IQR) cummulative exposure to
antiretroviral therapy was 40 (9–100) months. Among
these 30 patients on antiretroviral therapy when CMVI
was diagnosed, 20 (66%) of them had previously inter-
rupted antiretroviral therapy for longer than 3 months.
Sixteen (28%) patients had previously presented with
an opportunistic infection, the most frequent being P.
jirovecii in seven cases. A total of 38 (68%) patients re-
ported consumption of tobacco smoking, alcohol, illicit
drugs, or a combination of the three. Twenty (36%) pa-
tients had some co-morbidity associated with their HIV
infection, the most common one being chronic obstruct-
ive pulmonary disease in 8 (14%) cases. Nineteen (34%)
patients were admitted to the ICU and 14 of them re-
quired mechanical ventilation (Table 1).
Clinical presentation
The most frequent clinical presentation were systemic
symptoms with fever, cough and general malaise, in 43%
of the cases, This was followed by respiratory infection in
30% (mainly pneumonia) and gastrointestinal in 14% (col-
itis and esophagitis) (Table 1). The most common clinical
symptom was fever (59%). No patient had acute retinitis
or other ophthalmic involvement. The first choice of treat-
ment for CMVI was ganciclovir in 49 patients (88%), val-
ganciclovir in four and foscarnet in three. Patients under
ART treatment had the best improvement.
CMV was found in the blood of 38 (68%) patients, 14
(30%) BAL, and 4 (7%) in intestinal tissue. The diagnosis
of CMV was obtained by PCR from blood exclusively in
38 (68%) patients, PCR from BAL exclusively in 5 (9%),
isolation of the virus from BAL culture exclusively in 5
(9%), and PCR from intestinal biopsy in 4 (7%). In 4 pa-
tients, both the PCR and the culture from BAL were
positive for CMV.
The 17 patients who developed respiratory symptoms
were diagnosed with CMVI, PCR from blood, and the
patients with colitis symptoms, by PCR from the biopsy
of the affected organ. CMV was the only pathogen re-
covered in 13% of all the cases. The most frequent
microorganism found together with CMV was P. jirove-
cii (37%) followed by T. gondii (14.%). P jirovecii was
identified in 21 patients, but not all of them had clinical
presentation at admission, some of them had systemic
presentation as fever, general malaise, etc.
The CMV end-organ disease could only be detected in
4 patients, in which the virus was found in tissue biopsy.
Predictor factors of mortality
The 30-day mortality was 18% (10 patients) and 50% of
them had respiratory-associated infection. One patient
died in a conventional room and the rest (9 patients) in
the ICU. The mortality of the patients admitted to the
ICU was 47%. Drug use, previous opportunistic infection
were related with ICU admission (X2 = 7.165; p = 0.007;
X2 = 4.464, p = 0.035, respectively). The predictive vari-
ables associated with mortality, that were identified in
the univariate analysis were; ICU admission 32.4 (3.65–
287.06) p = 0.0001, mechanical ventilation 84 (8.27–
853.12) p = 0.0001, and ART 4.1 (0.97–17.31) p = 0.044,
these variables were assessed by multivariate analysis.
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Only mechanical ventilation was statistically significant
(p < 0.05), (Table 2).
The patients with co-infection by P. jirovencii pre-
sented no greater mortality than the non-coinfected ones
(X2 = 0.07; p = 0.792).
The relationship between CMV viral load in blood and
viral load in BAL and mortality was not statistically sig-
nificant (t = − 1.73; p = 0.09), mortality was (t = − 2.18;
p = 0.07). Neither the CD4 count nor the value viral load
was significant (Table 2). Regarding the patients admit-
ted to the ICU, the value of CMV viral load in blood
was not related to mortality (p < 0.424) even if they had
high viral loads.
Discussion
Our study shows the incidence of acute CMV in recent
years (1.7 cases per 1000 patient-years), which is higher
than previously reported in the early years of cART (0.6
cases per 1000 patients-year) [17], but lower than the
pre-ART era (7.34 cases per 1000 patients-year) [18].
This incidence increase is a matter of concern as it may
reflect an increment of susceptible population, since
there are still many patients with late diagnosis of HIV
infection, which leads to a delay in the initial treatment
with ART. Regarding clinical manifestations, the sys-
temic affectation in the form of bad general condition
and fever was the most common, followed by respiratory
manifestations, which is highly consistent with previous
literature [19–21]. In our study, despite the high number
of patients with immunosuppression (CD4 < 200 cells/
μl), we have not found any cases of ophthalmic
manifestation of CMV. Retinitis has been the most com-
mon manifestation of CMVI, accounting for about 85%
of all the cases [22], although other authors have also
found a estimated 80–90% decline on the incidence of
retinitis in the ART era [23, 24], probably because of the
earlier initiation of ART at HIV diagnosis [25]. ophthal-
moscopic examination and rigorous eye check up should
be a compulsory practice in every case of HIV/AIDS pa-
tients having CD4 count less than 100cells/μl and in
those patients with detectable CMV viremia, even in the
absence of any vision-related complaints.
Although patients receiving ART clinically evident
end-organ CMV disease may no longer be a common
problem thanks to the increasing success of ART, there
is growing evidence that the impact of the CMV chronic
infection remains highly relevant. This may be explained
by the immune activation and systemic inflammation
caused by CMV increasing the risk of HIV-related mor-
bidity and mortality [26, 27]. Despite this, our study did
not show a significant association between CMV viral
load and mortality. In our study we were unable to show
a poor outcome predictive value of CMV viral load in
blood, or viral load in BAL. To our knowledge, this find-
ing has not been previously reported and our results
suggest that further research should be conducted to
better understand its clinical relevance.
Given the nonspecific symptoms of CMVI and the
high mortality of these patients, it may be necessary to
consider requesting a diagnostic test for CMV when any
HIV patient consults with a widespread and/or infec-
tious systemic affectation even if it is respiratory











Age in years, Median (IQR)* 39 (31–47) 39 (31–47) 38 (31–50) 35 (28–42) 36 (34–51)
Sex, male n, (%) 44 (79) 13 (78) 21 (87) 7 (88) 1 (25)
On HAART**, yes n, (%) 14 (25) 1 (6) 7 (29) 5 (63) 4 (100)
Fever n, (%) 33 (59) 12 (71) 18 (75) 1 (13) 2 (50)
ICU admission n, (%) 19 (34) 8 (47) 7 (30) 1 (13) 2 (50)
Mechanical Ventilation, yes n, (%) 12 (21) 6 (35%) 3 (13) 1 (13) 1 (25)
Mortality n, (%) 10 (18%) 3 (18%) 4 (17) 1 (13) 1 (25)
Cd4 cells/mm3, Median (IQR)* 47 (18–85) 19 (10–45) 63 (22–97) 67 (43–206) 23 (14–69)
Cd8 cells/mm3, Median (IQR)* 514 (272–
828)
356 (189–860) 514 (289–653) 727 (494–941) 319 (123–649)




1.27 (0.49–4.03) 3.1 (0.8–9.1) 6.6 (0.95–18.4) 1.21 (0.1–4.8)




3.9 (1.2–43.6) 1.2 (0.7–13) 1.2 (0.56–31.1) 0.4 (0.1–122)
LDH° IU/L values [< 240], Median (IQR)* 657 (463–
1000)
891 (597–1333) 650 (427–809) 578 (441–865) 430 (351–454)
*Interquartile range. ** Highly active retroviral activity ***Cytomegalovirus °Lactate dehydrogenate. °Three patients were not included (1 cardiac, dermatologic and
hematological involvement)
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symptoms and fever. If the patient presents with respira-
tory symptoms, BAL must be considered since CMV iso-
lation from BAL samples showed to be a predictor of
death [28]. This is because, as is known, CMV may be
present in the BAL in a patient affected by P jirovencii,
although we can not really assert that CMV has a patho-
genic value in this coinfection, since it is essential to
confirm CMV disease In a biopsy of the affected organ,
so always treatment for CMV was started [29]..
We need to know the distinction between CMV end-
organ disease and CMV viral syndrome, the major dif-
ference is the detection, by biopsy, of CMV vat the
tissue.
Our study showed that patients with CMVI, coinfec-
tion by P. jirovencii did not present greater mortality
than the non-coinfected ones. These results should be
interpreted with caution, likely because the sample is
small.
For patients admitted to the ICU, it should be noted
that they had already been diagnosed with CMVI before
the admission, where a further increase in the rate of re-
activation by CMV among critically ill patients is already
known [30, 31]. Our study showed a 30-day mortality of
18% and the main cause was respiratory infection, which
contrasts with the study from Lichter et al. [32] where
the cardiovascular and neurological events, attributable
to the role of CMV coinfection in vascular/organ degen-
erative disorders in HIV-infected subjects, were the main
cause of mortality. However, this study was performed
in a different setting in which the patients were ART
treated and no evidence of CMVI was present and the
follow-up was much longer.
Limitations
Among the limitations of our study, we acknowledge
that this is a single-center, retrospective study, however,
our center is a reference center for HIV care around
5000 patients/year. We gathered a relatively high num-
ber of patients, followed in a similar way, through
several years of follow-up. The tissue biopsy was not al-
ways feasible, especially in patients with poor general
condition. In addition, diagnosis was based on laboratory
confirmation of CMVI. Due to the number of patients
we cannot affirm that the mortality was high.
Conclusion
We found an incidence of CMVI higher than that previ-
ously described. CMVI in our cohort predominantly af-
fects undiagnosed or untreated HIV-infected patients,
for whom the benefit of combination antiretroviral ther-
apy does not exist. Systemic manifestations were the
most common presentation. Neither CMV viral load in
BAL or in blood, were identified as risk factors for mor-
tality. These findings may be taken into account to in-
crease early HIV diagnosis and early CMV monitoring.
Abbreviations
ART: Antiretroviral therapy; BAL: Bronchoalveolar lavage;
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